Physician profile
Michael Pawlowsky
NPI 1649250416
$7,268.92
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,239 · 2020: $772 · 2021: $2,163 · 2022: $1,990 · 2023: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $104.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,970.20 | 2019-2022 | |
| Abbvie INC. | $1,432.14 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $608.77 | 2019-2022 | |
| Celgene Corporation | $366.21 | 2021-2022 | |
| Shionogi INC | $306.44 | 2019-2020 | |
| Gilead Sciences, INC. | $298.87 | 2019-2022 | |
| Pfizer INC. | $267.00 | 2019-2022 | |
| Ucb, INC. | $248.03 | 2019 | |
| Janssen Biotech, INC. | $213.35 | 2019-2022 | |
| Braintree Laboratories, INC. | $166.22 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $160.95 | 2021 | |
| Merck Sharp & Dohme LLC | $155.71 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $150.25 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $132.90 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $125.33 | 2020-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Concordia Pharmaceuticals INC. | $116.68 | 2019 | |
| Evoke Pharma, INC. | $100.59 | 2021-2022 | |
| Alfasigma USA, INC. | $86.46 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $76.74 | 2019-2022 | |
| Genzyme Corporation | $60.30 | 2022 | |
| Romark Laboratories, Lc | $57.80 | 2019-2020 | |
| Vivus LLC | $32.98 | 2019-2020 | |
| Allergan, INC. | $25.75 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $21.47 | 2022 | |
| Alnylam Pharmaceuticals INC. | $20.81 | 2022 | |
| Daiichi Sankyo INC. | $18.42 | 2019 | |
| Shire North American Group INC | $16.52 | 2019 | |
| Redhill Biopharma INC. | $16.40 | 2021 | |
| Intra-Sana Laboratories | $15.63 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pawlowsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.